SER 109

Drug Profile

SER 109

Alternative Names: SER-109

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator Seres Health
  • Developer Seres Therapeutics
  • Class Anti-infectives; Bacteria
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Clostridium infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Clostridium infections

Most Recent Events

  • 16 Mar 2017 Seres Therapeutics plans a phase II ECOSPOR III trial for Clostridium infections in USA
  • 31 Jan 2017 Pooled in-depth efficacy and safety analysis of phase II trial and open label extension study in Clostridium difficile infection released by Seres Therapeutics
  • 01 Oct 2016 Seres Therapeutics completes a phase II trial in Clostridium infections (Recurrent) in USA (PO) (NCT02437487)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top